BRAXF

Braxia Scientific Corp. [BRAXF] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BRAXF Stock Summary

In the News

08:11 29 Mar 2024 BRAXF

Braxia Scientific reports significant increase in treatment volumes across its clinics

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported a significant increase in treatment volumes across its clinics, which rose by 26.2% in fiscal 2023 to 3,516, compared to 2,785 treatments in the previous year. The company said its growth has been driven by increased demand across all five of its clinics.

08:47 29 Mar 2024 BRAXF

Braxia Scientific announces termination of Irwin Naturals merger LOI; retains strategic clinical assets

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) announced that Irwin Naturals Inc has terminated the non-binding amended and restated letter of intent (LOI) for a business combination between Irwin and Braxia, which the company called “disappointing”.   The medical research and telemedicine firm, however, said it remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry, which continues to evolve and consolidate.

06:46 29 Mar 2024 BRAXF

Braxia Scientific reports 50.5% increase in 3Q revenue; updates on acquisition by Irwin Naturals

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported third-quarter results that show a sharp rise in revenue as the company increased its in-clinic ketamine treatments and continued to expand its US telemedicine platform, KetaMD. The medical research and telemedicine company also updated investors on its proposed acquisition by Irwin Naturals Inc. (CSE:IWIN) after the two companies entered into a non-binding Letter of Intent (LOI) in January.

06:39 29 Mar 2024 BRAXF

Braxia Scientific closes first tranche of its non-brokered offering for aggregate proceeds of $751,218.83

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has closed the first tranche of its previously announced non-brokered offering resulting in the issuance of 13,658,524 units of the company at a price of 5.5 cents per unit for aggregate proceeds of $751,218.83. The company said it intends to use the net proceeds of the LIFE offering and the concurrent placement to support the rollout of its telemedicine platform in the United States, for clinic expansion in Canada and to continue intellectual property development, and the company expects to use the net proceeds of the concurrent placement for working capital and general corporate purposes.

08:41 29 Mar 2024 BRAXF

Braxia Scientific announces up to $1.5M offering and concurrent private placement

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an offering of up to 27,272,727 units of the company at a price of $0.055 each for aggregate proceeds of up to $1.5 million pursuant to the listed issuer financing exemption (LIFE) and a concurrent private placement of up to 7,272,727 units for aggregate gross proceeds of up to $400,000. The net proceeds of the LIFE offering will be used to support the rollout of the company's telemedicine platform in the United States, for clinic expansion in Canada, and to continue intellectual property development, Braxia said.

08:25 29 Mar 2024 BRAXF

Irwin Naturals announces LOI to acquire Braxia Scientific to create new market leader

Irwin Naturals Inc. (CSE:IWIN) said it has entered into a non-binding amended and restated Letter of Intent (LOI) for a business combination with Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) in a move it said will create a new market leader in North American mental health. The company noted that Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

09:04 29 Mar 2024 BRAXF

Irwin Naturals an Braxia Scientific partner to accelerate in-human development of new therapies for mental health

Irwin Naturals Inc. (CSE:IWIN) and Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) have signed a Letter of Intent (LOI) entering into a partnership to launch Clinical Research Services across Irwin's growing US-based network of clinics, Emergence. Under the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial research services beginning with at least five clinics in Florida.

07:22 29 Mar 2024 BRAXF

Braxia Scientific sees Q2 revenue increase, with in-clinic treatment up 34.5%

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an increase in revenues for its second quarter and the first half ended September 30, 2022, with in-clinic treatment rising by 34.5% as it continues to build on its core strengths and priorities.  The company also said it also evaluating strategic capital market opportunities to create shareholder value.

10:21 29 Mar 2024 BRAXF

Braxia Scientific says telemedicine provider KetaMD ramps up Florida operations in wake of Hurricane Ian

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced the expansion of its ketamine therapy program to help Floridians cope with mental health, including those affected by Hurricane Ian. Braxia's wholly-owned KetaMD subsidiary provides at-home ketamine treatments for Florida residents suffering from depression and related mental health conditions through telemedicine and a mobile app.

09:01 29 Mar 2024 BRAXF

Braxia Scientific launches KetaMD as first Florida patients complete initial virtual ketamine treatments at home

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has successfully launched KetaMD in the US state of Florida, adding new patients and completing initial ketamine treatments. Eligible patients, as determined by one of KetaMD's licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their homes, according to Braxia.

BRAXF Financial details

Company Rating
Sell
Market Cap
1.65M
Income
-9.64M
Revenue
2.21M
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-0.13
Forward P/E
-
PEG
0.03
P/S
0.74
P/B
2.62
P/C
-
P/FCF
-0.28
Quick Ratio
0.42
Current Ratio
0.48
Debt / Equity
-1.6
LT Debt / Equity
-1.37
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-16.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-17.11%
EPS Q/Q
240%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.26%
Inst Trans
1.13%
ROA
-374%
ROE
-401%
ROC
-5.28%
Gross Margin
11%
Oper. Margin
-253%
Profit Margin
-494%
Payout
-
Shs Outstand
138.64M
Shs Float
128.46M
-
-
-
-
Target Price
-
52W Range
0.004-0.021
52W High
-
52W Low
-
RSI
50.17
Rel Volume
0.08
Avg Volume
149.14K
Volume
11.75K
Perf Week
-1.54%
Perf Month
0%
Perf Quarter
-21.95%
Perf Half Y
-22.89%
-
-
-
-
Beta
1.528
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0064
Change
-6.43%

BRAXF Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric History 2020-03-312021-03-312022-03-31 2023-03-31
2.02K2.02K2.02K2.02K
Revenue per share
00.010.010.01
Net income per share
0-0.56-0.07-0.06
Operating cash flow per share
-0.01-0.03-0.03-0.03
Free cash flow per share
-0.01-0.03-0.03-0.04
Cash per share
0.020.070.050.01
Book value per share
0.030.10.050.01
Tangible book value per share
0.030.060.040
Share holders equity per share
0.030.10.050.01
Interest debt per share
0000
Market cap
22.94M75.15M10.52M5.9M
Enterprise value
22.08M64.1M2.01M4.59M
P/E ratio
-132.81-0.85-0.87-0.45
Price to sales ratio
108.2K74.527.083.13
POCF ratio
-79.42-14.86-2.33-0.8
PFCF ratio
-65.76-14.8-2.32-0.71
P/B Ratio
20.724.731.173.68
PTB ratio
20.724.731.173.68
EV to sales
104.17K63.571.352.44
Enterprise value over EBITDA
-129.6-6.02-0.28-0.67
EV to operating cash flow
-76.46-12.68-0.44-0.62
EV to free cash flow
-63.31-12.62-0.44-0.55
Earnings yield
-0.01-1.18-1.15-2.23
Free cash flow yield
-0.02-0.07-0.43-1.41
Debt to equity
00.010.020.13
Debt to assets
00.010.020.05
Net debt to EBITDA
5.021.041.190.19
Current ratio
19.574.473.811
Interest coverage
0-5.24K-1.45K-416.51
Income quality
1.670.060.370.56
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
322.066.134.352.9
Research and developement to revenue
235.851.960.130.05
Intangibles to total assets
00.380.150.22
Capex to operating cash flow
0.2100.010.12
Capex to revenue
-283.02-0.02-0.02-0.48
Capex to depreciation
-28.97-1.11-1.09-1.6
Stock based compensation to revenue
15.18K3.071.630.46
Graham number
0.051.130.280.1
ROIC
-0.16-0.67-0.77-3.89
Return on tangible assets
-0.15-7.76-1.23-4.36
Graham Net
0.020.050.040
Working capital
989.28K8.84M7.12M7.56K
Tangible asset value
1.11M8.85M7.19M736.67K
Net current asset value
989.28K8.8M6.99M-123.75K
Invested capital
00.010.020.13
Average receivables
056.72K462.23K609.97K
Average payables
01M1.32M875.89K
Average inventory
016.89K0.54.34K
Days sales outstanding
041.06199.0579.22
Days payables outstanding
1.26K184.9450.5575.18
Days of inventory on hand
1.35K000.6
Receivables turnover
08.891.834.61
Payables turnover
0.291.977.224.86
Inventory turnover
0.273.9M0610.7
ROE
-0.16-5.59-1.35-8.19
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.01-0.03000
Operating cash flow per share
-0.020000
Free cash flow per share
-0.02-0.01000
Cash per share
0.010.01000
Book value per share
0.030.01000
Tangible book value per share
0.010000
Share holders equity per share
0.030.01000
Interest debt per share
00000
Market cap
6.03M6.81M6.28M3.61M1.5M
Enterprise value
4.69M5.5M5.51M3.44M1.9M
P/E ratio
-0.69-0.22-1.96-3.3-0.41
Price to sales ratio
12.3313.0410.466.073.05
POCF ratio
-1.64-5.17-11.11-25.48-2.82
PFCF ratio
-1.66-5.05-11.08-25.48-2.77
P/B Ratio
0.764.247.816.74-4.1
PTB ratio
0.764.247.816.74-4.1
EV to sales
9.610.539.185.83.86
Enterprise value over EBITDA
-2.1-2.59-7.51-18.48-2.43
EV to operating cash flow
-1.27-4.17-9.75-24.33-3.57
EV to free cash flow
-1.29-4.08-9.72-24.33-3.51
Earnings yield
-0.36-1.12-0.13-0.08-0.6
Free cash flow yield
-0.6-0.2-0.09-0.04-0.36
Debt to equity
0.030.130.181.13-1.6
Debt to assets
0.020.050.050.210.25
Net debt to EBITDA
0.60.621.050.88-0.51
Current ratio
1.5410.580.480.18
Interest coverage
0-738.87-187.89-10.03-33.39
Income quality
1.70.170.70.520.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.273.40.750.31.27
Research and developement to revenue
0.1600.0300
Intangibles to total assets
0.690.220.320.30.37
Capex to operating cash flow
-0.010.02000.02
Capex to revenue
0.11-0.0600-0.02
Capex to depreciation
0.28-0.2-0.030-0.12
Stock based compensation to revenue
0.310.210.010.010.01
Graham number
0.080.060.010.010.01
ROIC
-0.29-1.19-0.78-0.16-1.31
Return on tangible assets
-0.74-2.54-0.44-0.13-0.62
Graham Net
000-0.01-0.01
Working capital
715.82K7.56K-752.78K-961.21K-1.81M
Tangible asset value
1.48M736.67K-64.17K-332.9K-1.23M
Net current asset value
580.6K-123.75K-879.63K-1.48M-2.31M
Invested capital
0.030.130.181.13-1.6
Average receivables
198.94K312.75K245.46K76.75K81.26K
Average payables
635.7K867.55K1.18M1.31M1.4M
Average inventory
44.68K9.03K4.34K00
Days sales outstanding
39.8670.4512.310.8316.64
Days payables outstanding
40.4264.29154.89205.84158.94
Days of inventory on hand
0.590.51000
Receivables turnover
2.261.287.328.315.41
Payables turnover
2.231.40.580.440.57
Inventory turnover
152.78176.086302031.28B00
ROE
-0.27-4.77-1-0.512.48
Capex per share
00000

BRAXF Frequently Asked Questions

What is Braxia Scientific Corp. stock symbol ?

Braxia Scientific Corp. is a CA stock , located in Mississauga of On and trading under the symbol BRAXF

What is Braxia Scientific Corp. stock quote today ?

Braxia Scientific Corp. stock price is $0.0064 today.

Is Braxia Scientific Corp. stock public?

Yes, Braxia Scientific Corp. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap